OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
SIHL.PSX56

Shifa International Hospitals Ltd

Healthcare Facilities & ServicesVerified

Shifa International Hospitals Ltd maintains a conservative capital structure, with a debt-to-equity ratio of 0.12, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.5, suggesting it can cover short-term obligations but with limited surplus. Free cash flow stands at PKR 1.58 billion, which is lower than operating cash flow of PKR 4.08 billion, reflecting capital expenditures of PKR 1.59 billion. Profitability metrics show a return on equity of 15.12% and a return on assets of 9.03%, both exceeding the typical thresholds for the healthcare industry. The company's net income of PKR 2.26 billion is supported by an operating income of PKR 4.54 billion, with a gross profit margin of 65.2%. The company's revenue is concentrated within Pakistan, with no disclosed international revenue segments. It operates through multiple subsidiaries, including Shifa Medical Center Islamabad and Shifa National Hospital Faisalabad, but does not provide segment-specific revenue breakdowns. Revenue for the latest period is PKR 27.97 billion, with no disclosed prior-year figures to assess growth. The company's capital expenditures of PKR 1.59 billion suggest ongoing investment in infrastructure, but the absence of prior-year data limits the ability to assess the growth trajectory. Risk factors include a medium liquidity rating and a note that net cash is negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the basic shares outstanding. No recent events, such as filings or transcripts, are provided in the input data to inform the narrative.

30-day price · SIHL.PSX+53.01 (+12.1%)
Low$431.00High$525.00Close$492.00As of12 May, 00:00 UTC
Profile
CompanyShifa International Hospitals Ltd
TickerSIHL.PSX
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. Shifa International Hospitals Ltd operates as a healthcare provider in Pakistan, offering medical centers, hospitals, organ transplant services, and support services including pharmacy and diagnostic services.

Classification. The company is classified under the Healthcare sector, specifically in the Healthcare Facilities & Services industry, with a confidence level of 0.92.

Shifa International Hospitals Ltd maintains a conservative capital structure, with a debt-to-equity ratio of 0.12, indicating a low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.5, suggesting it can cover short-term obligations but with limited surplus. Free cash flow stands at PKR 1.58 billion, which is lower than operating cash flow of PKR 4.08 billion, reflecting capital expenditures of PKR 1.59 billion. Profitability metrics show a return on equity of 15.12% and a return on assets of 9.03%, both exceeding the typical thresholds for the healthcare industry. The company's net income of PKR 2.26 billion is supported by an operating income of PKR 4.54 billion, with a gross profit margin of 65.2%. The company's revenue is concentrated within Pakistan, with no disclosed international revenue segments. It operates through multiple subsidiaries, including Shifa Medical Center Islamabad and Shifa National Hospital Faisalabad, but does not provide segment-specific revenue breakdowns. Revenue for the latest period is PKR 27.97 billion, with no disclosed prior-year figures to assess growth. The company's capital expenditures of PKR 1.59 billion suggest ongoing investment in infrastructure, but the absence of prior-year data limits the ability to assess the growth trajectory. Risk factors include a medium liquidity rating and a note that net cash is negative after subtracting total debt. The dilution risk is assessed as low, with no significant dilution potential in the basic shares outstanding. No recent events, such as filings or transcripts, are provided in the input data to inform the narrative.
Key takeaways
  • The company maintains a conservative debt-to-equity ratio of 0.12, indicating a low reliance on debt financing.
  • Return on equity of 15.12% and return on assets of 9.03% suggest strong profitability relative to industry norms.
  • Free cash flow of PKR 1.58 billion is available for reinvestment or shareholder returns, though capital expenditures are significant.
  • Revenue is concentrated within Pakistan, with no disclosed international operations or segment-specific revenue breakdowns.
  • Liquidity is rated as medium, with a current ratio of 1.5, and dilution risk is assessed as low.
  • # RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyPKR
Revenue$27.97B
Gross profit$18.24B
Operating income$4.54B
Net income$2.26B
R&D
SG&A
D&A
SBC
Operating cash flow$4.08B
CapEx-$1.59B
Free cash flow$1.58B
Total assets$25.01B
Total liabilities$10.08B
Total equity$14.93B
Cash & equivalents
Long-term debt$1.81B
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0
FY-1
FY-2
FY-3
FY-4
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0
FY-1
FY-2
FY-3
FY-4
PeriodOCFCapExFCFSBC
FY0
FY-1
FY-2
FY-3
FY-4
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$14.93B
Net cash-$1.81B
Current ratio1.5
Debt/Equity0.1
ROA9.0%
ROE15.1%
Cash conversion1.8%
CapEx/Revenue-5.7%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Pharmaceuticals · cohort 25 companies
MetricSIHL.PSXActivity
Op margin16.2%18.2% medp25 18.2% · p75 24.6%bottom quartile
Net margin8.1%14.7% medp25 11.7% · p75 28.1%bottom quartile
Gross margin65.2%19.7% medp25 19.7% · p75 39.8%top quartile
R&D / revenue24.3% medp25 6.6% · p75 24.3%
CapEx / revenue-5.7%4.9% medp25 4.2% · p75 6.3%bottom quartile
Debt / equity12.0%71.3% medp25 19.0% · p75 91.7%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-10 12:17 UTC#df91e781
Source: analysis-pipeline (hybrid)Generated: 2026-05-10 12:19 UTCJob: 5213e251